Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Joshua Schimmer has reiterated an Overweight rating on Cabaletta Bio (NASDAQ:CABA), maintaining a $50 price target.

April 05, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Joshua Schimmer has reiterated an Overweight rating on Cabaletta Bio, maintaining a $50 price target.
The reiteration of an Overweight rating and a high price target by a reputable analyst like Joshua Schimmer suggests a strong vote of confidence in Cabaletta Bio's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100